The ADA 2025 presentations will cover: Phase 1 Trial Results for HM15275, Robust anti-obesity effect and mechanistic insights of HM15275 in animal models of obesity, Mechanistic insights into HM15275s improved quality of weight loss compared to tirzepatide (Zepbound), Weight loss and differentiated body composition improvement effects of HM17321, Glycemic control improvement observed with HM17321, and Synergistic effects on body composition improvement when combining HM15275 and HM17321 A large delegation from Hanmis R&D Center will attend ADA 2025 to present poster sessions showcasing the companys novel therapeutic approaches in obesity treatment and to explore potential collaborations with leading global pharmaceutical companies
This depends on the kind of mobile phase (Yilmaz et al
Weeks 5-10: Reduce intensity by 30 to 50 percent
Providers should still document BMI at treatment initiation, qualifying comorbidities, medication indication, and lifestyle intervention in the chart
People turn to semaglutide, a medication originally designed for diabetes, because it has been shown to help with weight loss